Molecular heterogeneity in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1

Human Genomics

Volumn 6, Issue 1, 2012, Pages

  Thomas, Laura ^a   Mautner, Victor Felix ^b   Cooper, David N ^a   Upadhyaya, Meena ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Malignant peripheral nerve sheath tumors; Molecular heterogeneity; Neurofibromatosis type 1; TP53

Indexed keywords

PROTEIN P53; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; RETINOBLASTOMA PROTEIN; TP53 PROTEIN, HUMAN;

ARTICLE; CARCINOGENESIS; CDKN2A GENE; CLINICAL ARTICLE; CORRELATION ANALYSIS; GENE; GENE MUTATION; GENETIC HETEROGENEITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1; NF1 GENE; PTEN GENE; RB1 GENE; SOMATIC MUTATION; TP53 GENE; GENE LOCUS; GENETIC MARKER; GENETICS; METABOLISM; MUTATION; NERVE SHEATH TUMOR; RISK FACTOR; TUMOR SUPPRESSOR GENE;

GENES, NEUROFIBROMATOSIS 1; GENES, P16; GENES, P53; GENETIC LOCI; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84876553530     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/1479-7364-6-18     Document Type: Article

References (47)

1. Upadhyaya M: Neurofibromatosis type 1: diagnosis and recent advances. Expert Opin Med Diagn 2010, 4:307-322.
2. Ferner RE: The neurofibromatoses. Pract Neurol 2010, 10:82-93.
3. Upadhyaya M: Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci 2011, 16:937-951.
4. Jett K, Friedman JM: Clinical and genetic aspects of neurofibromatosis 1. Genet Med 2010, 12:1-11.
5. Upadhyaya M: Neurofibromatoses (Monographs in Human Genetics). In NF1 gene structure and NF1 genotype/phenotype correlations. Edited by Kaufmann D. Switzerland: S Karger AG; 2008:46-62.
6. Cichowski K, Jacks T: NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001, 104:593-604.
7. Arun D, Gutmann DH: Recent advances in neurofibromatosis type 1. Curr Opin Neurol 2004, 17:101-105.
8. Thomas L, Spurlock G, Eudall C, Thomas NS, Mort M, Hamby SE, Chuzhanova N, Brems H, Legius E, Cooper DN, Upadhyaya M: Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas. Eur J Hum Genet 2012, 20(4):411-419.
9. Garcia-Linares C, Fernández-Rodríguez J, Terribas E, Mercadé J, Pros E, Benito L, Benavente Y, Capellà G, Ravella A, Blanco I, Kehrer-Sawatzki H, Lázaro C, Serra E: Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH. Hum Mutat 2011, 32(1):78-90.
10. Gottfried ON, Viskochil DH, Fults DW, Couldwell WT: Molecular, genetic, and cellular pathogenesis of neurofibromas and surgical implications. Neurosurgery 2006, 58:1-16.
11. Brekke HR, Ribeiro FR, Kolberg M, Agesen TH, Lind GE, Eknaes M, Hall KS, Bjerkehagen B, van den Berg E, Teixeira MR, Mandahl N, Smeland S, Mertens F, Skotheim RI, Lothe RA: Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol 2010, 28:1573-1582.
12. Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM: Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 1999, 155:1855-1860.
13. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN: Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 1999, 155:1879-1884.
14. Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R: Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch 2002, 440:610-615.
15. Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, Dumanski JP, Guha A, Mautner V, Upadhyaya M: High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res 2008, 14:1015-1024.
16. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T: Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286:2172-2176.
17. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle DE, Watson MA, Perry A, Gutmann DH, Ratner N: Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006, 66:2584-2591.
18. Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, Wu H: PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci USA 2009, 106:19479-19484.
19. Upadhyaya M, Spurlock G, Monem B, Thomas N, Friedrich RE, Kluwe L, Mautner V: Germline and somatic NF1 gene mutations in plexiform neurofibromas. Hum Mutat 2008, 29:112-122.
20. Thomas L, Kluwe L, Chuzhanova N, Mautner V, Upadhyaya M: Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden. Neurogenetics 2010, 11:391-400.
21. Visvader JE: Cells of origin in cancer. Nature 2011, 469:314-322.
22. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, et al: Subtypes of medulloblastoma have distinct developmental origins. Nature 2010, 468:1095-1099.
23. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY, Martinelli C, Lusis EA, Hegedus B, Gutmann DH, Giovannini M: Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 2011, 30(20):2333-2344.
24. Singh DK, Ku CJ, Wichaidit C, Steininger RJ III, Wu LF, Altschuler SJ: Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities. Mol Syst Biol 2010, 6:369.
25. Liu J, Lau SK, Varma VA, Moffitt RA, Caldwell M, Liu T, Young AN, Petros JA, Osunkoya AO, Krogstad T, Leyland-Jones B, Wang MD, Nie S: Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano 2010, 4:2755-2765.
26. Friedman J: Gutmann DH, Maccollin M, Riccardi VM: Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore: The Johns Hopkins University Press; 1999.
27. Le LQ, Parada LF: Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene 2007, 26:4609-4616.
28. Upadhyaya M, Han S, Consoli C, Majounie E, Horan M, Thomas NS, Potts C, Griffiths S, Ruggieri M, von Deimling A, Cooper DN: Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Hum Mutat 2004, 23:134-146.
29. McDaniel T, Carbone D, Takahashi T, Chumakov P, Chang EH, Pirollo KF, Yin J, Huang Y, Meltzer SJ: The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res 1991, 19:4796.
30. Hartmann A, Rösner U, Schlake G, Dietmaier W, Zaak D, Hofstaedter F, Knuechel R: Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest 2000, 80:709.
31. Belchis DA, Meece CA, Benko FA, Rogan PK, Williams RA, Gocke CD: Loss of heterozygosity and microsatellite instability at the retinoblastoma locus in osteosarcomas. Diagn Mol Pathol 1996, 5:214-219.
32. Yandell DW, Dryja TP: Detection of DNA sequence polymorphisms by enzymatic amplification and direct genomic sequencing. Am J Hum Genet 1989, 45:547-555.
33. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 1995, 11:210-212.
34. Pollock PM, Welch J, Hayward NK: Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res 2001, 61:1154-1161.
35. Li YL, Tian Z, Wu DY, Fu BY, Xin Y: Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol 2005, 11:285-288.
36. Liapis H, Marley EF, Lin Y, Dehner LP: p53 and Ki-67 proliferating cell nuclear antigen in benign and malignant peripheral nerve sheath tumors in children. Pediatr Dev Pathol 1999, 2:377-384.
37. Otis CN, Krebs PA, Quezado MM, Albuquerque A, Bryant B, San Juan X, Kleiner D, Sobel ME, Merino MJ: Loss of heterozygosity in p53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behaviour. Hum Pathol 2002, 31:233-238.
38. Götte K, Riedel F, Neubauer J, Schäfer C, Coy JF, Hörmann K: The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer. Int J Oncol 2001, 19:331-336.
39. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005, 97:1808-1815.
40. Camp RL, Chung GG, Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8:1323-1327.
41. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL: Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in preinvasive disease. Br J Cancer 2011, 104:120-127.
42. Lennington WJ, Jensen RA, Dalton LW, Page DL: Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 1994, 73:118-124.
43. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
44. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
45. Whitehall VL, Wynter CV, Walsh MD, Simms LA, Purdie D, Pandeya N, Young J, Meltzer SJ, Leggett BA, Jass JR: Morphological and molecular heterogeneity within non microsatellite instability-high colorectal cancer. Cancer Res 2002, 62:6011-6014.
46. Stingl J, Caldas C: Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007, 7:791-799.
47. Katz D, Lazar A, Lev D: Malignant peripheral nerve sheath tumor (MPNST): the clinical implications of cellular signalling pathways. Exp Rev Mol Med 2009, 11:e30.